Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 17/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 16/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 11/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.37 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.37 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.37 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.37 |
| ▸ | SLC6A11 | P48066 | 2/20 | 0.37 |
| ▸ | SLC6A13 | Q9NSD5 | 2/20 | 0.37 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.37 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.37 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16408333 | 1.00 | SLC6A4 (0.46) | SLC6A4SLC6A2KCNH2SLC6A3CYP2D6 | |
| SCHEMBL16408232 | 1.00 | SLC6A4 (0.46) | SLC6A4SLC6A2KCNH2SLC6A3CYP2D6 | |
| SCHEMBL13478888 | 0.90 | CHRM1 (0.42) | SLC6A4SLC6A2KCNH2SLC6A3CYP2D6 | |
| SCHEMBL24327704 | 0.85 | SLC6A4 (0.46) | SLC6A4SLC6A2KCNH2SLC6A3CYP2D6 | |
| SCHEMBL30419345 | 0.85 | SLC6A4 (0.46) | SLC6A4SLC6A2KCNH2SLC6A3CYP2D6 | |
| SCHEMBL13673559 | 0.85 | SLC6A4 (0.46) | SLC6A4SLC6A2KCNH2SLC6A3CYP2D6 | |
| Hydrochloric Acid SCHEMBL15808506 | 0.81 | SLC6A4 (0.43) | SLC6A4SLC6A2KCNH2SLC6A3CYP2D6 | |
| SCHEMBL30419169 | 0.80 | SLC6A4 (0.46) | SLC6A4SLC6A2KCNH2SLC6A3CYP2D6 | |
| SCHEMBL30419218 | 0.80 | SLC6A4 (0.46) | SLC6A4SLC6A2KCNH2SLC6A3CYP2D6 | |
| SCHEMBL30419208 | 0.80 | SLC6A4 (0.46) | SLC6A4SLC6A2KCNH2SLC6A3CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240299352-A1 | COMBINATION THERAPIES WITH SETD2 INHIBITORS | Epizyme, Inc. | 2024-09-12 | — | — | US | disclosed |
| US-20230133671-A1 | SETD2 INHIBITORS AND RELATED METHODS AND USES, INCLUDING COMBINATION THERAPIES | Epizyme, Inc. (US) | 2023-05-04 | — | — | US | disclosed |
| EP-3022194-B1 | INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INT (DE) | 2017-05-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240299352-A1 | COMBINATION THERAPIES WITH SETD2 INHIBITORS | SETD2, CARM1, SETDB1 | SLC6A4 4362/4885SLC6A2 3379/4885KCNH2 3596/4885 |
| US-20230133671-A1 | SETD2 INHIBITORS AND RELATED METHODS AND USES, INCLUDING COMBINATION THERAPIES | EZH2, HDAC2, SETD2 | SLC6A4 4630/4885SLC6A2 4135/4885KCNH2 4617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.